http://online.liebertpub.com/doi/pdfplus/10.1089/dia.2012.1221 ATTD 2013 Oral Presentations (Lots of interesting abstracts) O-5 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN CHILDREN AT ONSET OF TYPE-1 DIABETES J. Jager-Amsellem1, C. Hasselmann1, E. Perrodeau1, N. Faure1, I. Mercat1, F. Labarthe1, E. Bonnemaison2 1 CHU Tours, 2 Unite? de Spe?cialite?s Pe?diatriques, CHU Tours, Tours, France Objective: Continuous subcutaneous insulin infusion (CSII) has been used in children with diabetes for many years, but its use at onset of diabetes has been little studied. Our aim was to compare CSII started at onset of type-1 diabetes with multiple daily injections (MDI) to assess metabolic control and safety. Research design and methods: 41 children treated by CSII at onset of diabetes ( January 2005?July 2009) were paired with 41 newly diagnosed children treated by MDI. They were paired by age and gender. Data such as HbA1c, BMI, insulin requirement, severe hypoglycemia, diabetic ketoacidosis and hospitalization related to the diabetic condition, were recorded retrospectively over a period of 18 months. Results: The proportion of children with an HbA1c remaining below 7.5% during the entire study was signiﬁcantly greater in the CSII group (43.3% vs. 8.7%). Insulin doses (IU/kg/d) were lower in the CSII group after 1 year of treatment (0.6 vs. 0.71 IU/ kg/d). No difference was found regarding BMI, severe hypoglycemia or hospitalization. The length of the initial hospitalization was longer in the CSII group. Conclusions: Our study suggests that the use of CSII, when started at onset of type-1 diabetes, allows better metabolic control than MDI and requires lower insulin doses. CSII appears as safe as MDI regarding severe hypoglycemia and diabetic ketoacidosis.